Although BCR–ABL inhibitor based treatment helps majority of CML patients to lead normal life till treatment continue but unfortunately few patients i.e. 20-30% develop TKI resistance, either primary or secondary and are prone to progress toward the AP or BP of the disease (Kang et al., 2006). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.